Paladin, Isotechnika submit Voclera in Canada

Paladin Labs (TSX:PLB) and Isotechnika (TSX:ISA) have submitted Voclera, a treatment for moderate to severe psoriasis, for marketing approval in Canada. Voclera was discovered by Isotechnika and has been in development since the late 1990s. Paladin acquired the Canadian rights for Voclera from Isotechnika in June, 2009. “This submission is the culmination of almost 15 years [...]

Paladin in licence pact with ProStrakan

Paladin Labs (TSX:PLB) and Britain’s ProStrakan Group (LSE:PSK) have unveiled a new strategic relationship that will give Paladin an exclusive licence to ProStrakan’s products for certain emerging territories in exchange for an assignment of ProStrakan’s existing secured debt, with the addition of certain conversion rights. Under the accord, Paladin, which currently distributes ProStrakan’s Abstral and [...]

Isotechnika licenses voclosporin to ILJIN Life

Isotechnika Pharma (TSX:ISA) has entered into a development, distribution and licence agreement with ILJIN Life Science, a member of the ILJIN Group of South Korea, for the further clinical and commercial development of its voclosporin drug. Isotechnika has granted ILJIN an exclusive license to voclosporin for transplant and autoimmune indications for the U.S. and other [...]

Versant ups Paladin Labs to buy

Versant Partners upgraded Paladin Labs (TSX:PLB) to “buy” from “neutral,” raising its 12-month price target to $31.50 from $29 after the company posted third quarter results. The stock was quoted at $28.01 Thursday afternoon. Analyst Doug Loe writes that while Paladin’s third quarter revenue was a bit lighter than projected, EBITDA was historically strong and [...]

Labopharm, Paladin expand licensing pacts

Labopharm (TSX:DDS; NASDAQ:DDSS) and Paladin Labs (TSX:PLB) have expanded their commercial relationship through three licensing and distribution agreements for two of Labopharm’s products in certain jurisdictions. In the first accord, Labopharm has granted Paladin the exclusive right, subject to Labopharm’s co-promote right for Canada, to market and sell its Intellitab twice-daily formulation of oxycodone-acetaminophen in [...]

You asked a CEO

Four weeks ago, we asked you what’s on your mind. Specifically, what would you like to “Ask a CEO?”  Frankly, we were heartened and surprised by your response. So as promised, this week’s Feature, which coincides with the first anniversary of biotuesdays.com’s launch, is a rundown of the questions and the answers we received. We [...]

Cash-rich Paladin on the acquisition trail

Paladin Labs (TSX:PLB) is sitting on a war chest of some $97 million that’s growing by the quarter and itching to be deployed. “We’re going to invest in opportunities with a high return on investment,” CEO Jonathan Goodman, says in an exclusive interview with biotuesdays.com.  “But I’m not going to bet the company on a [...]

« Previous Page